150 related articles for article (PubMed ID: 38602057)
21. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia.
Wang X; Raoufinia A; Bihorel S; Passarell J; Mallikaarjun S; Phillips L
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):150-164. PubMed ID: 34979059
[TBL] [Abstract][Full Text] [Related]
23. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
[TBL] [Abstract][Full Text] [Related]
24. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
[TBL] [Abstract][Full Text] [Related]
26. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.
Hard ML; Wehr AY; Du Y; Weiden PJ; Walling D; von Moltke L
J Clin Psychopharmacol; 2018 Oct; 38(5):435-441. PubMed ID: 30015676
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
Girardi P; Del Casale A; Rapinesi C; Kotzalidis GD; Splendori F; Verzura C; Trovini G; Sorice S; Carrus D; Mancinelli I; Comparelli A; De Filippis S; Francomano A; Ballerini A; Marcellusi A; Mennini FS; Ducci G; Sani G; Pompili M; Brugnoli R
Hum Psychopharmacol; 2018 May; 33(3):e2658. PubMed ID: 29766576
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
Ishigooka J; Noda T; Nishiyama K; Tamaru N; Shima T; Yamasaki Y; Tadori Y
Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Jun; 36(3):63-8. PubMed ID: 27506082
[TBL] [Abstract][Full Text] [Related]
30. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.
Kane JM; Schooler NR; Marcy P; Correll CU; Achtyes ED; Gibbons RD; Robinson DG
JAMA Psychiatry; 2020 Dec; 77(12):1217-1224. PubMed ID: 32667636
[TBL] [Abstract][Full Text] [Related]
31. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy.
Baune BT
Curr Med Res Opin; 2024 Jan; 40(1):87-96. PubMed ID: 37999650
[TBL] [Abstract][Full Text] [Related]
32. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
Citrome L
Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
[TBL] [Abstract][Full Text] [Related]
33. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
Yan T; Greene M; Chang E; Touya M; Broder MS
J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
[TBL] [Abstract][Full Text] [Related]
34. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.
Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
CNS Drugs; 2017 Apr; 31(4):273-288. PubMed ID: 28258365
[TBL] [Abstract][Full Text] [Related]
35. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Citrome L
Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
[TBL] [Abstract][Full Text] [Related]
36. Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
T'jollyn H; Venkatasubramanian R; Neyens M; Gopal S; Russu A; Nandy P; Perez-Ruixo JJ; Ackaert O
Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):491-506. PubMed ID: 38769284
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
Boulton DW; Kollia G; Mallikaarjun S; Komoroski B; Sharma A; Kovalick LJ; Reeves RA
Clin Pharmacokinet; 2008; 47(7):475-85. PubMed ID: 18563956
[TBL] [Abstract][Full Text] [Related]
38. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
Aggarwal A; Gopalakrishna G; Lauriello J
Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
[TBL] [Abstract][Full Text] [Related]
39. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]